公开(公告)号：US11833142B2

公开(公告)日：2023-12-05

申请号：US17493055

申请日：2021-10-04

Applicant: Novartis AG

Inventor： Rohan Eric John Beckwith ,  Simone Bonazzi ,  Artiom Cernijenko ,  Fupeng Ma ,  Nathaniel F. Ware

IPC: A61K31/454 ,  A61P35/00 ,  A61K31/4545 ,  A61K31/498 ,  C07D401/04 ,  C07D401/14

CPC classification number: A61K31/454 ,  A61K31/4545 ,  A61K31/498 ,  A61P35/00 ,  C07D401/04 ,  C07D401/14

Abstract: The present disclosure provides a compound of Formula (I′):






or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ra, Rb, Rx, R1, R2, X2, and q are as defined herein, and methods of making and using same.

公开(公告)号：US20230381168A1

公开(公告)日：2023-11-30

申请号：US18328682

申请日：2023-06-02

Applicant: ANeuroTech IP BV

Inventor： Erik Buntinx

IPC: A61K31/4545 ,  A61K45/06 ,  A61P25/24

CPC classification number: A61K31/4545 ,  A61K45/06 ,  A61P25/24

Abstract: The present invention relates to the treatment of affective disorders, in particular partially responsive depression, in which subjects are treated with dopamine D4 and 5-HT2A receptor antagonist, reverse agonist, or partial agonist as an adjunctive therapy.

公开(公告)号：US11819498B2

公开(公告)日：2023-11-21

申请号：US17136608

申请日：2020-12-29

Applicant: UNM RAINFOREST INNOVATIONS

Inventor： Vojo P. Deretic ,  Jia Cassano ,  Bhawana Bissa

IPC: A61K31/4164 ,  A61K31/4184 ,  A61K31/438 ,  A61K31/133 ,  A61K31/198 ,  A61K31/155 ,  A61K31/4439 ,  A61K31/585 ,  A61K31/7004 ,  A61K31/618 ,  A61K31/4365 ,  A61K31/496 ,  A61K31/519 ,  A61K31/437 ,  A61K31/485 ,  A61K31/4545 ,  A61K31/4418 ,  A61K31/192 ,  A61K31/58 ,  A61K31/365

CPC classification number: A61K31/4439 ,  A61K31/133 ,  A61K31/155 ,  A61K31/192 ,  A61K31/198 ,  A61K31/365 ,  A61K31/4164 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/438 ,  A61K31/4365 ,  A61K31/4418 ,  A61K31/4545 ,  A61K31/485 ,  A61K31/496 ,  A61K31/519 ,  A61K31/58 ,  A61K31/585 ,  A61K31/618 ,  A61K31/7004

Abstract: The present invention is directed to the discovery that AMPK activation through Galectin 9 induces autophagy and affects other related processes in response to lyosomal damage which occurs and the use of that mechanism in the treatment of autophagy disease states and/or conditions. The use of modulators of AMPK and optionally a modulator of Galectin 9, TAK1 and/or a lysosomotropic agent for the treatment of autophagy-mediated disease states and/or conditions is described as are pharmaceutical compositions.

公开(公告)号：US11814361B2

公开(公告)日：2023-11-14

申请号：US17381500

申请日：2021-07-21

Applicant: BioAxone BioSciences, Inc.

Inventor： Kenneth M. Rosen ,  Matthew D. Abbinanti ,  Joerg Ruschel ,  Lisa McKerracher ,  Lisa Bond Moritz

IPC: C07D401/12 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/551 ,  A61K45/06 ,  C07B59/00 ,  C07C55/14

CPC classification number: C07D401/12 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/551 ,  A61K45/06 ,  C07B59/002 ,  C07C55/14 ,  C07B2200/05 ,  C07B2200/07 ,  A61K31/4725 ,  A61K2300/00 ,  A61K31/4545 ,  A61K2300/00 ,  A61K31/551 ,  A61K2300/00

Abstract: BA-1049 (R) and its active metabolite are disclosed. Also disclosed are pharmaceutical formulations containing BA-1049 (R) or its active metabolite.

公开(公告)号：US11806337B2

公开(公告)日：2023-11-07

申请号：US17875216

申请日：2022-07-27

Applicant: Sanford Burnham Prebys Medical Discovery Institute

Inventor： Stephen Gardell ,  Anthony B. Pinkerton ,  Eduard Sergienko ,  Hampton Sessions

IPC: A61K31/4409 ,  A61K31/196 ,  A61K31/245 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/417 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/422 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4418 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/47 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/50 ,  A61K31/505 ,  A61K31/5377 ,  A61K31/5386 ,  C07C275/42 ,  C07D213/40 ,  C07D213/56 ,  C07D213/643 ,  C07D213/73 ,  C07D213/74 ,  C07D231/12 ,  C07D233/64 ,  C07D237/08 ,  C07D239/26 ,  C07D249/04 ,  C07D261/08 ,  C07D263/32 ,  C07D277/28 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D498/08

CPC classification number: A61K31/4409 ,  A61K31/196 ,  A61K31/245 ,  A61K31/415 ,  A61K31/417 ,  A61K31/4155 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/422 ,  A61K31/426 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4355 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/443 ,  A61K31/444 ,  A61K31/4406 ,  A61K31/4418 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/47 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/50 ,  A61K31/505 ,  A61K31/5377 ,  A61K31/5386 ,  C07C275/42 ,  C07D213/40 ,  C07D213/56 ,  C07D213/643 ,  C07D213/73 ,  C07D213/74 ,  C07D231/12 ,  C07D233/64 ,  C07D237/08 ,  C07D239/26 ,  C07D249/04 ,  C07D261/08 ,  C07D263/32 ,  C07D277/28 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D498/08

Abstract: Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.

公开(公告)号：US20230346696A1

公开(公告)日：2023-11-02

申请号：US18022619

申请日：2021-08-31

Applicant: PHILIP MORRIS PRODUCTS S.A.

Inventor： Fabiana Spadaro ,  Gérard Zuber

IPC: A61K9/00 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/465 ,  A61K9/16

CPC classification number: A61K9/0075 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/465 ,  A61K9/1623 ,  A61K9/1694

Abstract: A method of forming an inhalable powder composition including combining sugar or a sugar alcohol with an active agent and a liquid carrier to form a liquid mixture, and spraying drying the liquid mixture at a spray drying temperature to form crystalline dry powder particles. The spray drying temperature is greater than a glass transition temperature of the sugar or sugar alcohol.

公开(公告)号：US20230330080A1

公开(公告)日：2023-10-19

申请号：US18001655

申请日：2021-06-25

Applicant: Cambridge Enterprise Limited

Inventor： Ingo Ringhausen ,  Eugene Park ,  David Cavalla

IPC: A61K31/4545 ,  A61K31/407 ,  A61K31/553 ,  A61K31/4184 ,  A61K31/635 ,  A61K31/7076 ,  A61P35/02

CPC classification number: A61K31/4545 ,  A61K31/407 ,  A61K31/553 ,  A61K31/4184 ,  A61K31/635 ,  A61K31/7076 ,  A61P35/02

Abstract: The disclosure provides a PKC inhibitor and a cytotoxic agent for use in therapy, wherein the PKC inhibitor reaches a peak concentration in a subject prior to the cytotoxic agent reaching a peak concentration. The PKC inhibitor and the cytotoxic 5 agent may be used to treat cancer or an autoimmune disease.

公开(公告)号：US20230330072A1

公开(公告)日：2023-10-19

申请号：US18210719

申请日：2023-06-16

Applicant: Allergan Pharmaceuticals International Limited

Inventor： Joel M. Trugman ,  Ramesh Boinpally ,  Abhijeet Jakate ,  Michelle Finnegan

IPC: A61K31/4375 ,  A61P25/06 ,  A61K31/4545

CPC classification number: A61K31/4375 ,  A61K31/4545 ,  A61P25/06

Abstract: The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.

公开(公告)号：US20230322772A1

公开(公告)日：2023-10-12

申请号：US18045605

申请日：2022-10-11

Applicant: Sprint Bioscience AB

Inventor： Johan Lindström ,  Rickard Forsblom ,  Fredrik Rahm ,  Jenny Viklund

IPC: A61K31/444 ,  A61K31/506 ,  A61K31/5377 ,  A61K38/45 ,  C07D471/04 ,  A61K31/4545 ,  A61K31/496 ,  A61P35/00

CPC classification number: C07D471/04 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K38/45 ,  A61P35/00 ,  A61N5/10

Abstract: The invention provides novel azaindolylpyridone and diazaindolylpyridone compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer, type II diabetes, inflammatory diseases, autoimmune diseases, neurodegenerative disorders, cardiovascular disorders and viral infections;





wherein R2, R3 and X are as defined in the specification.

公开(公告)号：US11779578B2

公开(公告)日：2023-10-10

申请号：US17125426

申请日：2020-12-17

Applicant: Kymera Therapeutics, Inc.

Inventor： Matthew M. Weiss

IPC: A61K31/4545 ,  A61P35/00 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/519 ,  C07D417/14 ,  C07D487/04 ,  C07D519/00

CPC classification number: A61K31/4545 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/519 ,  A61P35/00 ,  C07D417/14 ,  C07D487/04 ,  C07D519/00

Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.